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A B S T R A C T
Rifampicin is the most important antibiotic in use for the treatment of tuberculosis (TB). Preclinical and clinical
data suggest that higher doses of rifampicin, resulting in disproportionally higher systemic exposures to the drug,
are more eﬀective. Serum concentrations of rifampicin are the intermediary link between the dose administered
and eventual response and only protein-unbound (free) rifampicin is pharmacologically active. The objective of
this work was to develop an ultra performance liquid chromatography assay for protein-unbound rifampicin in
serum with ultraﬁltration, carried out at a sample temperature of 37 °C, suitable for measurement of con-
centrations achieved after currently used and higher doses of rifampicin.
Human serum was equilibrated at 37 °C and ultraﬁltrated at the same temperature in a Centrifree YM-30
ultraﬁltration device, followed by dilution of the ultraﬁltrate with methanol and ascorbic acid. Unbound ri-
fampicin was analyzed using ultra performance liquid chromatography with a BEH C18 column, isocratic elution
and ultra-violet (UV) detection. The run time was 5 min.
The assay was linear over the concentration range of 0.065–26 mg/L rifampicin in ultraﬁltrate. Accuracies for
measurement of rifampicin in ultraﬁltrate were 97% and 102% at the higher and lower limits of quantitation.
Accuracy of the ultraﬁltration process cannot be established, as it is not possible to spike blank serum with
known amounts of protein-unbound rifampicin. Within- and between-day precision of the method including
ultraﬁltration as well as after ultraﬁltration were within prespeciﬁed limits (CV < 10%). Dilution of the ul-
traﬁltrate with methanol and ascorbic acid kept rifampicin in solution and prevented it from degradation.
Rifampicin loss during the ultraﬁltration process and variation in analytical results when using two diﬀerent
batches of ultraﬁltration devices were both limited. Processed ultraﬁltrate samples were stable for 3 days in the
autosampler.
The developed method can be applied in pharmacokinetic research, studying exposure-response relationships
for rifampicin when administered at higher than currently used doses.
1. Introduction
Rifampicin is one of the pivotal drugs for the treatment of tu-
berculosis (TB), which is the leading infectious disease in terms of
mortality worldwide [1]. A rifampicin dose of 10 mg/kg daily com-
bined with pyrazinamide enabled shortening of the duration of TB
treatment to six months decades ago [2]. This 10 mg/kg dose (often
450 or 600 mg, dependent on weight) was chosen in the 1960s and
1970s based on considerations related to pharmacokinetics, cost at the
time, and presumed adverse eﬀects [3]. Accumulating data in mice and
humans suggest, however, that this 10 mg/kg daily dose is at the lower
end of the dose-response curve [4–9]. Our group has performed a dose
escalating study in pulmonary TB patients showing that doses up to
35 mg/kg resulted in a more than proportional (ninefold) increase in
exposure to rifampicin in plasma, which was safe and well tolerated in
small groups [7]. This 35 mg/kg dose of rifampicin combined with
isoniazid, pyrazinamide and ethambutol was able to reduce time to
sputum culture conversion and may shorten pulmonary TB treatment
[8]. A higher dose of rifampicin also reduced mortality in a small study
among patients with TB meningitis, the most severe form of TB [9].
Clearly higher doses of rifampicin require more extensive follow-up
research, including pharmacokinetic (PK) and pharmacokinetic-
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pharmacodynamic (PK-PD) evaluation.
In pharmacokinetic studies with rifampicin, measurement of the
drug in plasma or serum is usually related to the total (protein-unbound
plus bound) concentration of rifampicin. An equilibrium between total
and protein-unbound concentrations is commonly assumed, yet protein-
unbound (free) rather than total drug concentrations are preferably
used in concentration-response evaluations [10], as only protein-un-
bound drugs are pharmacologically active and diﬀuse (or are being
actively transported) into tissues and to the sites of action [11,12]. In a
recent pharmacokinetic study with standard dose rifampicin we as-
sessed a two-fold interindividual variation in the unbound rifampicin
fraction [13]. This interindividual variability in the free fraction indeed
shows that measurement of solely total concentrations could be mis-
representative of the relevant exposure. It is currently unknown what
the free fraction of rifampicin is after administration of higher doses
that result in much higher rifampicin exposures, possibly associated
with saturation of plasma or serum proteins that bind rifampicin.
Clearly the redevelopment of rifampicin as a TB drug warrants the
development of an analytical method for protein-unbound rifampicin
concentrations achieved after administration of high doses of the drug.
Previously we measured free rifampicin concentrations after stan-
dard doses using ultraﬁltration at room temperature. In ultraﬁltration,
centrifugal forces are employed as the driving force for the passage of
serum water across a ﬁlter membrane [14]. The aim of the current
project was to develop and validate a new ultraﬁltration method for the
measurement of the free, active concentration of rifampicin at 37 °C,
enabling for PK and PK-PD studies with higher doses of rifampicin.
2. Materials and methods
2.1. Chemicals and materials
Rifampicin (cas.nr. 13292-46-1, purity 98%, see Fig. 1 for chemical
structure), acetic acid (100%), ammonium acetate (> 98%), acetoni-
trile and methanol of LC–MS quality were purchased from Merck
(Darmstadt, Germany). Ascorbic acid was purchased from Bufa (IJs-
selstein, The Netherlands). HPLC quality water was obtained with a
Veolia Purelab ﬂex 4 system from Veolia (Ede, The Netherlands).
Centrifree YM-30 ultraﬁltration ﬁlter devices were from Millipore B.V.
(Amsterdam, The Netherlands). Drug free human serum was obtained
from Sanquin blood bank (Nijmegen, The Netherlands) and was stored
at −40 °C.
2.2. Preparation of stocks
Two rifampicin stock solutions containing 1000 mg/L of rifampicin
with 200 mg/L ascorbic acid were prepared in methanol: HPLC quality
water (4:1%v/v). Ascorbic acid is added to rifampicin to protect it from
degradation [15]. Stocks were stored at −40 °C.
2.3. Preparation of calibration stocks for the calibration curve
For the preparation of the calibration curve, one of the rifampicin
stock solutions was diluted with methanol to achieve six calibration
stocks of 1.3–2.6–7.8–26–78–260 mg/L (calibration stocks 1–6) and
were stored at−40 °C until analysis. All stocks were shown to be stable
for at least 12 months.
2.4. Calibration curve for unbound rifampicin in serum ultraﬁltrate
Calibration curve standards could not exist of serum samples spiked
with known amounts of rifampicin that are subsequently being ultra-
ﬁltrated, as the analytical method aims to measure unbound con-
centrations of rifampicin and these concentrations cannot be set (or
‘spiked’) in serum. Therefore the calibration curve consisted of blank
serum ultraﬁltrate spiked with rifampicin. Blank ultraﬁltrate was ob-
tained by ultraﬁltration of drug free human serum.
The calibration curve was made freshly on the day of analysis. First,
solutions of rifampicin in blank ultraﬁltrate were prepared. For stan-
dard 0, 200 μL blank ultraﬁltrate was used. For standards 1–6, 10 μL of
one of the calibration stocks 1–6 was added to 190 μL blank ultra-
ﬁltrate. For standard 7, 20 μL calibration stock 6 was mixed with 180 μL
blank ultraﬁltrate. The resulting calibration curve concentrations of
rifampicin were 0.065–0.13–0.39–1.3–3.9–13–26 mg/L. Secondly,
200 μL volumes of each of these solutions of rifampicin in ultraﬁltrate
were transferred into maximum recovery® vials (Waters) with 400 μL of
methanol: ascorbic acid 20 mg/mL in water (40:1%v/v). The vials were
closed with a polypropylene screw cap with silicon/PTFE septum to
prevent evaporation. The use of methanol in the samples was pivotal to
keep rifampicin dissolved and prevent it from sticking to inserts and
vials, whereas ascorbic was essential to prevent disintegration of the
drug.
2.5. Internal quality control samples: stocks and sample preparation
Although serum could not be spiked with predetermined protein-
unbound concentrations of rifampicin, it was deemed desirable to have
internal quality control over the sample preparation procedure. To this
end, internal quality control (QC) samples were prepared from the
second stock solution (see above) resulting in total (protein-bound plus
unbound) concentrations of 1.5, 10 and 61 mg/L in serum, designated
as QC Low, Medium and High respectively. The QC samples were stored
at −80 °C and found to be stable for at least 26 months.
Sample processing for these QC samples was identical to sample
Fig. 1. Chemical structure of rifampicin.
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processing of patient samples. Since there was no known nominal
concentration of unbound rifampicin in these samples, the mean pro-
tein-unbound concentrations of rifampicin of these QC samples as
measured during validation (n = 15) were taken as internal QC con-
centration values. During analysis of samples for pharmacokinetic re-
search, QC Low, Medium and High samples are to be analyzed within
each run and a maximum deviation of 15% from the concentrations
measured during the validation will be accepted.
2.6. Sample preparation
Whole blood with rifampicin was centrifuged within 4 h after blood
withdrawal and the resulting serum was prepared further or stored at
−80 °C. A volume of 0.5 mL of serum (sample, QC or drug free human
serum) was pipetted into the sample reservoir of a Centrifree YM-30
tube (Fig. 2, part 2). For 60 min the tube was equilibrated at 41 °C at
1 x g within a Rotanta 460 R centrifuge with ﬁxed angle rotor 5645
(radius 132 mm, angle 25°) to reach a sample temperature of 37 °C. The
centrifugal force was only 1 x g during this equilibration period, as the
centrifuge had to be put ‘on’ to develop any temperature, yet the ul-
traﬁltration process should not start in this temperature equilibration
period. Then for 20 min the tube was centrifuged at 41 °C at 1650 x g
whereas the sample retained its temperature of 37 °C. The setting of the
Rotanta 460 R centrifuge at 41 °C resulted in a sample temperature of
37 °C, based on validation of sample temperatures with a calibrated
thermometer. Finally, 200 μL of the clear ultraﬁltrate in the ultraﬁltrate
cup (Fig. 2, part 4) was transferred into a maximum recovery® vial
(Waters) with 400 μL of methanol: ascorbic acid 20 mg/mL water
(40:1%v/v). The vials were closed with a polypropylene screw cap with
silicon/PTFE septum to prevent evaporation. Each of the standards,
samples and QC’s were mixed before injection into the UPLC system.
2.7. UPLC-UV analysis
The Acquity UPLC system consisted of a model BSM solvent delivery
pump, a model SM autosampler, a model CM column manager and a
model TUV UV detector. Separation was carried out on a BEH C18
column (100 × 2.1 mm ID; particle size,1.7 μm) with the column
temperature set at 45 °C. The mobile phase consisted of 35% acetoni-
trile and 65% 0.05 M acetate buﬀer pH 4.0. Flow rate was 0.5 mL/min
and the total run time was 5 min. UV detection was set at 334 nm.
Analytical runs were controlled and processed by Empower software
(all by Waters, Etten-Leur, The Netherlands).
2.8. Validation procedures
The validation of the assay in ultraﬁltrate was based on the most
recent versions of the guidelines on bioanalytical method validation of
the European Medicines Agency [16] and the FDA [17]. In addition, we
studied validation parameters speciﬁcally related to ultraﬁltration.
2.8.1. Selectivity
Various drugs potentially co-administered with rifampicin were
tested for interference at their therapeutic serum concentrations.
Furthermore, serum of six patients without TB medication was eval-
uated for interference by endogenous substances. The presence of in-
terfering components was accepted if the response was less than 20% of
the lower limit of quantitation (LLOQ) for rifampicin.
2.8.2. Carry-over
Carry-over was assessed by injecting blank samples after the cali-
brator at the higher limit of quantitation (HLOQ). Carry-over in the
blank sample following the highest concentration calibrator had to be
less than 20% of the LLOQ.
2.8.3. Accuracy, precision and linearity
Five replicates of samples of rifampicin in ultraﬁltrate at the LLOQ
and HLOQ were analyzed during three diﬀerent days, in order to de-
termine accuracy and within-day and between-day precision of the
method without the ultraﬁltration step. To analyse these samples, six
calibration concentration levels were used, in addition to the blank
sample which was not incorporated in the calibration line. In each
validation run the six calibrators were analysed in duplicate. For the
LLOQ, the percent deviation from the nominal concentration (accuracy)
and the relative standard deviation (precision) had to be less than 20%
and for the HLOQ both these measures had to be less than 15%.
For each replicate measurement, the concentrations measured in the
LLOQ and HLOQ samples were divided by the nominal concentrations.
To assess accuracy, the mean ratio of measured concentrations versus
nominal concentrations (n = 15 at each concentration level, i.e. at the
LLOQ or HLOQ) was calculated and multiplied by 100.
One-way Analysis of Variance (ANOVA) was used to assess the
within-day and between-day precision at each of the two (LLOQ or
HLOQ) concentrations, using the run day as the classiﬁcation variable.
The error mean square or mean square within groups (ErrMS), the day
mean square or mean square among groups (DayMS), and the grand
mean (GM) of all 15 measurements across the three run days were
obtained from the ANOVA. The estimate of the within-day and be-
tween-day precision at every concentration was calculated as follows:
Within-day precision = ((ErrMS)0.5/GM) × 100%
Between-day precision = ([(DayMS-ErrMS)/n]0.5/GM) × 100%
in which n is the number of replicate measurements within each day
We also wanted to validate the within-day and between-day preci-
sion of the analytical method with the ultraﬁltration step. To this end,
the three internal QC samples in serum were evaluated for within-day
and between-day precision, by performing the analytical method in-
cluding the ultraﬁltration step on ﬁve replicates of each QC sample and
during three diﬀerent days. Relative standard deviations for within-day
and between-day imprecision had to be less than 15%. Accuracy for
resulting unbound concentrations could not be assessed in these in-
ternal QC samples, as the nominal value for the unbound concentra-
tions cannot be preset or spiked.
Linear regression analysis was used to assess the linearity of the
calibration curves in each validation run. Duplicate responses were
used for each concentration, then transformed with a log-log ﬁt and
submitted to linear regression analysis. The blank was not taken into
consideration.
A signiﬁcant F-value would indicate linearity between analytical
Fig. 2. Centifree Ultraﬁltration Device.
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response and concentration and the correlation coeﬃcient r (or coef-
ﬁcient of determination, r2) was used as a measure for the strength of
the association.
2.8.4. Dilution integrity
After ultraﬁltration, QC High was diluted twice and four times with
blank ultraﬁltrate, and each dilution was performed and measured ﬁve
times. Since there was no known nominal concentration of unbound
rifampicin, the mean concentration found during validation (n = 15)
was taken as nominal (target) value. The percent deviation between the
mean concentrations after dilution as compared to the nominal value
before dilution and the relative standard deviation in measurement of
each diluted sample had to be less than 15%.
2.8.5. Stability
The stability of processed samples in the autosampler was tested. All
processed samples (standards, blank, LLOQ, QCH, QCM, QCL and
HLOQ) obtained at the ﬁrst day of assessment of accuracy and precision
(see above, ﬁve replicates of rifampicin in ultraﬁltrate at the LLOQ and
HLOQ levels and ﬁve replicates of the three internal QC samples in
serum) were re-analyzed after three days. For each sample, the per-
centage of concentrations obtained after three days in the autosampler
compared to the initially measured concentration was calculated.
2.8.6. Additional validation parameters – recovery of the ultraﬁltration
process
In addition to validation parameters required by these guidelines,
parameters associated with the use of the ultraﬁltration device
Centrifree YM-30 were validated.
The recovery of the ultraﬁltration process of rifampicin was assessed
to ﬁnd out if all rifampicin could be accounted for and no rifampicin
was lost during ultraﬁltration, also considering the limited solubility of
rifampicin. Recovery was assessed for QC Low, QC Medium and QC
High by
– measuring the amount of protein-bound rifampicin (in μg) as present
in the sample reservoir of the Centrifree YM-30 ﬁlter device (part 2
in Fig. 2) after ultraﬁltration;
– measuring the amount of protein-unbound rifampicin (in μg) as
present in the ﬁltrate cup of the Centrifree YM-30 ﬁlter (part 4 in
Fig. 2) after ultraﬁltration;
– adding up protein-bound and unbound amounts of rifampicin after
ultraﬁltration;
– and comparing the total amount of rifampicin after ultraﬁltration to
the total amount before ultraﬁltration.
Each of the amounts in μg was calculated by multiplication of
measured concentrations and volumes (amount = concen-
tration * volume).
In a formula:
=
× + ×
= ×
Recovery 100%
* (vol. RIF conc. ) (vol. RIF Conc. )
vol. ( 0.25ml) RIF Conc.
bound bound unbound unbound
ultrafiltrated serum total
Each of the items in this formula was assessed as follows:
– vol. bound: the sample reservoir was weighed after ultraﬁltration and
empty. The diﬀerence in these weights equals to the weight of the
bound fraction. The volume of the bound fraction was next calcu-
lated by the weight of the bound fraction divided by its density
(1,05 g/ml, see below).
– vol. unbound: the ﬁltrate cup was weighed after and before ultra-
ﬁltration. The diﬀerence in these weights equals to the weight of the
unbound fraction. The volume of the unbound fraction was next
calculated by the weight of the unbound fraction divided by its
density (1,01 g/ml, see below).
– RIF conc. unbound: The unbound rifampicin concentrations in the
ﬁltrate cup were measured with the method described in this article.
– RIF conc. total: The total rifampicin concentrations before ultra-
ﬁltration were analyzed with a validated method with the same
UPLC-UV analysis but with another pre-treatment of the samples. To
100 μL plasma, 200 μL methanol: acetonitrile, 1: 1 and 10 μL as-
corbic acid 20 mg/mL was added. The sample was thoroughly mixed
and centrifuged for 5 min. Then 100 μL 0.05 M acetate buﬀer pH 4.0
was added before mixing and centrifuging again. Ten μl of the clear
supernatant was injected. This assay was linear over the con-
centration range of 0.125–30 mg/L plasma. Accuracies in the LLOQ,
QC Low (2.94 mg/L), QC Medium (11.0 mg/L), QC High (22.1 mg/
L) and HLOQ were 101%, 100%, 101% 101% resp. 99%%. Within-
and between-day coeﬃcients of variation were < 3.0 resp. <
0.9%% in plasma. Samples > HLOQ were pre-diluted.
– RIF conc.bound: The rifampicin concentrations in the bound fraction
on the sample reservoir were analyzed with the same validated
method for total rifampicin. The bound fraction on the sample re-
servoir was loosened from the sample reservoir by centrifugation of
the reservoir upside down, followed by application of the method
for total concentrations on the sample.
The density of the bound fraction was assessed by weighing ﬁve
replicates of a set volume of bound fraction from the sample reservoir.
The density of the unbound fraction was assessed by weighing ﬁve
replicates of ultraﬁltrate out of the ﬁltrate cup.
2.8.7. Additional validation parameters – batch-to-batch diﬀerence in
ultraﬁltration devices
The batch-to-batch diﬀerence of the Centrifree YM-30 ultraﬁltration
device was validated. Unbound rifampicin in QC High and Low were
analysed in ﬁvefold with two diﬀerent batches. The diﬀerence in mean
concentrations measured with the two batches had to be less than 15%.
3. Results
3.1. Selectivity and carry-over
Most drugs tested did not interfere with the retention of rifampicin
(Table 1), except for amphotericin B. Serum of six patients without TB
medication was evaluated and found to be free from potential en-
dogenous or other interferences.
Typical chromatograms of unbound rifampicin serum samples are
shown in Fig. 3.
Carry-over in the blank sample following the high concentration
calibrator proved not to be greater than 20% of the LLOQ.
3.2. Accuracy, imprecision and linearity
The results of the determination of accuracy and imprecision of the
assay without (i.e. after) the ultraﬁltration step are presented in
Table 2a. These results show that the method is accurate at the LLOQ
and HLOQ (accuracy of 102 and 97%) and precise. The maximum
within-day and between-day coeﬃcients of variation occurred at the
LLOQ and were 8.8% and 5.6%, respectively.
Table 2b shows the results of analysis of ﬁve replicates of serum QC
Low, Medium and High samples, using the whole method with the ul-
traﬁltration step on three diﬀerent days. Mean protein-unbound con-
centrations of 0.144 mg/L, 1.11 mg/L and 13.9 mg/L were measured in
QC Low, Medium and High and these measures will be used as internal
QC target values during routine analysis.For a new batch of QC’s these
target values have to be established again considering that every serum
may give diﬀerent target values. Of note, the free fraction of protein-
unbound versus total rifampicin concentrations decreased from QC Low
to QC High (Table 2b). Within-day and between-day precision of the
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whole method with the ultraﬁltration step complied with the preset
requirements (CV < 15).
The calibration curves were linear over the concentration range of
0.65–26 mg/L unbound rifampicin by using log peak height vs log
concentration (F = 22133, P = 5.71E-21). The regression coeﬃcients
(r2) of all three calibration curves during validation of unbound ri-
fampicin in serum were 0.9996 ± 0.0001.
3.3. Dilution integrity
The percent deviation between the mean concentration of ultra-
ﬁltrated QC High after dilution compared to the nominal QC High
concentration before dilution was 3%, both after twice and four times
dilution of the QC High ultraﬁltrate. The relative standard deviations in
measurement of each diluted sample were 2.3% and 1.3% after two-
fold and four-fold dilutions, respectively.
3.4. Stability
Processed samples of unbound rifampicin proved to be stable with
mean concentrations of 101% of the initial concentrations after 3 days.
3.5. Additional validation parameters
Results presented in Table 3 show that no rifampicin is lost during
sample pre-treatment. For QC Low, QC Medium and QC High the re-
coveries were 96%, 95% and 95% with a precision coeﬃcient of var-
iation of 1.4%, 2.5% and 6.8%.
The diﬀerence in mean concentrations of protein-unbound ri-
fampicin for QC High and QC Low measured with two batches of the
Centrifree YM-30 ultraﬁltration devices was 3.4% and 1.6%.
4. Discussion
We described and validated a bio-analytical method using UPLC-UV
for the measurement of protein-unbound rifampicin in human serum
after ultraﬁltration at a sample temperature of 37 °C. Previously, we
measured total and protein-unbound rifampicin plasma concentrations
in malnourished and well-nourished TB patients and brieﬂy described
our bio-analytical method [13]. However, that method was not opti-
mized to measure at a sample temperature of 37 °C while retaining
compound solubility and stability. Furthermore, the current method
also covers much higher protein-unbound concentrations, which are
relevant after administration of rifampicin at higher doses [6–9]. Fi-
nally, the previous validation did not evaluate the presence of batch-to-
batch diﬀerences in ultraﬁltration devices that have been reported for a
bio-analytical method measuring free concentrations of rifapentine
[18].
Our new analytical method measured free rifampicin concentrations
using ultraﬁltration. In ultraﬁltration, centrifugal forces are employed
as the driving force for the passage of plasma or serum water across a
ﬁlter membrane [14]. Besides ultraﬁltration other methodologies are
available to determine plasma protein binding of drugs, such as ultra-
centrifugation and equilibrium dialysis. Equilibrium dialysis avoids the
nonspeciﬁc binding and relatively large plasma volumes often asso-
ciated with ultracentrifugation and ultraﬁltration [19]. However,
equilibrium dialysis can be time consuming and labour-intensive in
terms of preparation time and time to equilibration, making it less at-
tractive for pharmacokinetic assessments.
Clearly, measurement of protein-unbound concentrations with ul-
traﬁltration involves more than straightforward ultraﬁltration and
subsequent measurement of drugs. Ultraﬁltration brings along speciﬁc
analytical challenges and certainly warrants a well-considered valida-
tion.
First, it is not possible to assess the accuracy of bio-analytical
techniques that evaluate protein-unbound plasma or serum concentra-
tions of drugs. This is because it is impossible to spike serum with a
certain protein-unbound concentration of a drug and there is no way to
retrieve information on the true equilibrium between protein-bound
and protein-unbound drug in these samples. We still wanted to have
internal control over the ultraﬁltration step during routine analysis and
assessed protein-unbound rifampicin concentrations in three internal
QC serum samples, to be used as target values in routine analysis.
Replicate analysis of these internal QC samples also allowed us to assess
within-day and between-day precision of the analytical method with
the ultraﬁltration step included. Of course we also assessed accuracy
and precision for the analytical steps after ultraﬁltration.
Secondly, various experimental conditions and additional validation
parameters have to be considered when developing ultraﬁltration
methods. We paid a lot of attention to performing ultraﬁltration at body
temperature, as it is described that temperature could inﬂuence the
equilibrium of bound versus unbound drug in serum or plasma [20]. It
is hypothesized that the unbound drug fraction at physiological tem-
perature (37 °C) could be larger compared to room temperature, due to
a decrease in the binding force at higher temperatures [21]. In our
recent publication on the eﬀect of nutritional status on protein binding
of rifampicin administered in standard doses, we reported a small in-
crease in free fraction (+1.1%) for plasma samples measured at 37 °C
compared to results of the same method performed at room tempera-
ture. This increase in rifampicin free fraction in relation to a change in
experimental temperature is in agreement with sparse data for other
drugs as published in the literature [22].
Of note, our work revealed that the temperature setting of a cen-
trifuge does not represent the temperature within the centrifuged
Table 1
Possible co-administered drugs tested.
acetominophen domperidone lamivudine rilpivirine
acyclovir efavirenz lidocaine ritonavir
amphotericin Ba emtricitabine lopinavir saquinavir
amikacin erythromycin methadone SQ109
amoxicillin ethambutol moxiﬂoxacin stavudine
atazanavir etravirine naproxen sulfamethoxazole
carbamazepine famotidine nelﬁnavir N4-acetylsulfamethoxazole
clarithromycin phenobarbital nevirapine sulfametrole
clindamycin phenytoin oﬂoxacin N4-acetylsulfametrole
clofazimine ﬂuconazole oxazepam tenofovir
caﬀeine folic acid oxcarbazepine trimetoprim
dapsone ganciclovir pentamidine valproic acid
mono-acetyl dapson indinavir pyrazinamide zalcitabine
darunavir isoniazid pyrimethamine zidovudine
didanosine itraconazole raltegravir
dolutegravir ketoconazole rifabutin
a Co-elutes with rifampicin.
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sample. In order to validate our sample temperature before and during
centrifugation, we performed experiments in which a volume of 0.5 mL
water was pipetted in six Centrifree YM-30 devices, which were set in
diﬀerent positions in the rotor to reach a sample temperature of 37 °C
and retain this temperature during ultraﬁltration. The experiments re-
vealed that the time for equilibration within our speciﬁc centrifuge was
60 min at 1 × g at a set temperature of 41 °C. Next, the samples were
centrifuged for 20 min at 1650 × g, according to the manual of the
Centrifree YM-30 device, at a set temperature of 41 °C. Under these
conditions, the temperature of all samples remained 37 °C and the same
settings were used for the validation of the method.
Sample pH is another parameter that may aﬀect the free fraction
[22]. The pH of blood in the body is kept constant at pH 7.4 with the
help of carbonate as the main regulatory buﬀer system. Ex vivo, pH may
increase due to loss of carbon dioxide during storage or sample pro-
cessing and ultraﬁltration can increase the pH of the sample up to pH 8
in our hands. We have not evaluated whether such a pH diﬀerence is
relevant to the free fraction of rifampicin and this is a limitation of our
analytical method.
As additional validation parameters, we evaluated the recovery of
the ultraﬁltration process and demonstrated that no rifampicin was lost
during ultraﬁltration. We also assessed the batch-to-batch variation in
analytical results when using diﬀerent batches of ultraﬁltration devices.
As a third item related to ultraﬁltration, we would like to highlight
that we encountered speciﬁc challenges during method development
related to solubility and stability of rifampicin after ultraﬁltration.
More speciﬁcally, we observed decreased solubility of rifampicin in
ultraﬁltrate compared to plasma. Probably because of the absence of
proteins after ultraﬁltration, rifampicin preferred to stick to every insert
or vial available to us rather than remain in solution in ultraﬁltrate,
especially in low volumes. This did not result in linear calibration
curves. By adding 200 μL of ultraﬁltrate to a maximum recovery vial
with 400 μL of methanol, the calibration curve became linear. The
second challenge we encountered was the instability of rifampicin in
Fig. 3. panel A: Chromatogram of a blank ultraﬁltrate sample.
panel B: Chromatogram of a spiked calibration standard containing 1.3 mg/L rifampicin in ultraﬁltrate.
panel C: Chromatogram of QC Low (1.5 mg/L of rifampicin) after ultraﬁltration.
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the processed sample during the chromatographic quantiﬁcation. Since
ascorbic acid was added as a stabilizer in our method for total (bound
plus unbound) rifampicin, we also supplemented the processed un-
bound rifampicin sample with ascorbic acid, enabling that no cooling
was needed to prevent degradation of rifampicin during analysis.
The developed method is suitable for measurement of protein-un-
bound, active concentrations of rifampicin at various doses. The LLOQ
for rifampicin in ultraﬁltrate was set at a concentration of 0.065 mg/L,
which corresponds to total (unbound plus bound) concentrations of
0.325–0.65 mg/L, based on 80–90% protein binding [13,23]. The
HLOQ for unbound rifampicin was 26 mg/L, which would amount to a
total concentration ranging from 130 to 260 mg/L. Evidence from the
validation of our method suggests, however, that saturation of proteins
may occur at higher concentrations, as reﬂected in an increase in free
fraction from 9% to 22% (and a corresponding decrease in protein
binding from 91% to 78%) when total concentrations rise from 1.7 to
64 mg/L (Table 2b). In any case, the upper limit of the range of our
method will certainly exceed protein-unbound peak concentrations in
African TB patients that received up to 35 mg/kg of rifampicin for two
weeks [7], ensuring that the current method can be applied to assess
free rifampicin concentrations of individuals taking higher than stan-
dard dosing of rifampicin.
5. Conclusions
An assay was developed and validated for the determination of
protein-unbound (active, free) rifampicin in human serum by ultra-
ﬁltration at a sample temperature of 37 °C. Rifampicin could be kept in
solution in ultraﬁltrate by addition of methanol and was stable after
addition of ascorbic acid. Subsequent analysis took place with
Table 2
Accuracy and precision of rifampicin determination in serum and ultraﬁltrate.a (A) Accuracy and precision of rifampicin measurement in ultraﬁltrate (analytical method without, i.e. after
ultraﬁltration). (B) Precision of rifampicin measurement in serum (whole analytical method with ultraﬁltration)
(A)
Sample Concentration UFb spiked (mg/l) Accuracy (n = 15) (%) Within-day imprecision (CV%) Between-day imprecision (CV%)
LLOQ 0.0639 102 8.8 5.6
HLOQ 25.6 97 5.3 2.1
(B)
Sample Measured Serum concentration
spiked (mg/l)
Measured unbound
concentrationc (mg/l)
Free fraction
(%)d
Accuracy (n = 15)
(%)e
Within-day imprecision
(CV%)
Between-day imprecision
(CV%)
QC Low 1.70 0.144 8.5 – 3.8 0.0f
QC Medium 10.8 1.11 10.3 – 3.2 1.4
QC High 64.1 13.9 21.7 – 3.1 2.8
a At each concentration level, ﬁve replicates of samples were analyzed during three diﬀerent days (n = 15 measurements in total). Analysis of variance was used to assess the within-
day and between-day precision at each concentration level (see text).
b UF: ultraﬁltrate.
c The measured protein-unbound concentrations of rifampicin in QC samples are to be used as internal QC target concentration values during routine analysis. See text.
d The free fraction increases (and the corresponding protein binding decreases) with increasing total (bound plus unbound) serum concentrations, probably due to saturation of protein
binding sites. See text.
e It is not possible to assess the accuracy of bio-analytical techniques that evaluate plasma or serum protein binding. This is because it is impossible to spike serum with a certain
protein-unbound concentration of a drug. See text.
f In case the between-day imprecision is 0.0%, no additional variation upon the within-day imprecision is observed as a result of performing the assay on diﬀerent days.
Table 3
Recovery of the ultraﬁltration of rifampicin (RIF).
QC weight RIF Conc. weight RIF Conc. RIF Conc. Recoverya Mean CV
bound (g) bound (μg/mL) unbound (g) unbound (μg/mL) total (μg/mL)
Low 0.209 3.94 0.285 0.143 1.70 97.20% 95.8 1.4
0.224 3.67 0.268 0.143 96.50%
0.224 3.65 0.269 0.147 96.20%
0.217 3.72 0.253 0.15 95.00%
0.219 3.63 0.273 0.144 93.90%
Medium 0.230 22.1 0.259 1.06 10.8 94.60% 94.5 2.5
0.233 21.4 0.257 1.10 93.10%
0.212 23.4 0.276 1.09 92.80%
0.206 24.1 0.284 1.15 93.60%
0.21 25.0 0.289 1.11 98.50%
High 0.217 137 0.27 12.9 64.1 99.30% 95.4 6.8
0.215 130 0.265 14.0 95.00%
0.236 131 0.266 13.8 103.30%
0.196 127 0.27 13.8 86.00%
0.212 130 0.267 13.5 93.50%
a See text for explanation.
=
=
× + ×
= ×
× + ×
×
Recovery 100%*
100%
*
(vol.bound RIF conc.bound) (vol.unbound RIF Conc.unbound)
vol.ultrafiltrated serum ( 0.5ml) RIF conc.total
(weightbound / densitybound RIF conc.bound) (weightunbound / densityunbound RIF conc.unbound)
0.5 RIF conc.total
.
The density of the bound and unbound fractions were 1.05 g/ml and 1.01 g/ml, respectively.
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ultraperformance liquid chromatography with UV detection. The assay
can be used to measure unbound rifampicin concentrations when this
drug is administered in high doses and such analyses are relevant in the
redevelopment of this pivotal TB drug.
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